Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

June 18th 2024

The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.

FDA Approved - chrisdorney - stock.adobe.com.jpg
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

March 7th 2024

Red Blood Cells - Design Cells stock.adobe.com
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Highlights from ASH 2023
ICYMI: Highlights From ASH 2023

December 20th 2023

Zanubrutinib rendering | Image credit: molekuul.be - stock.adobe.com
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Continuing Medical Education
View All
November 10th 2024

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

December 18, 2024 | 1:00 PM & 8:00 PM ET
November 10th 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
November 10th 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer

More News

Older depressed man
November 11th 2020

Male, White, Older Patients With Leukemia at Heightened Risk of Suicide, Study Finds

Jared Kaltwasser
In what is believed to be the first study of its kind, investigators found patients with leukemia face a higher risk of suicide than the general public, especially if they had acute myeloid leukemia.
Hospital corridor sign
November 5th 2020

Patients With ALL Have High Readmission Risk Post Chemotherapy, but Hospitals Can Change That

Jared Kaltwasser
Many patients with acute lymphoblastic leukemia (ALL) who undergo chemotherapy end up back in the hospital within 30 days. A new study points out the reasons and opportunities for prevention.
Michael R. Green, PhD, MD Anderson
November 3rd 2020

Dr Michael Green Explains the Link Between Monocyte-Like Cells, Neurotoxicity After CAR T Therapy

Immune-associated neurotoxicity in patients following chimeric antigen receptor (CAR) T-cell therapy may be due to monocyte-like cells in infusion products, explained Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Prior Malignancy Linked to Risk of Secondary Malignancy in Follicular Lymphoma
October 29th 2020

Prior Malignancy Linked to Risk of Secondary Malignancy in Follicular Lymphoma

Jared Kaltwasser
Previous research has found a link between a prior malignancy and secondary primary malignancy risk in patients with multiple myeloma. A new study suggests a similar association in follicular lymphoma.
Case Report Suggests Nivolumab Is Effective in Burkitt Lymphoma
October 26th 2020

Case Report Suggests Nivolumab Is Effective in Burkitt Lymphoma

Jared Kaltwasser
A 72-year-old patient with Burkitt lymphoma was successfully treated with nivolumab after standard-of-care chemotherapy failed.
Michael R. Green, PhD, MD Anderson
October 23rd 2020

Dr Michael Green Discusses Understanding Patient Response to CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.
Review Lays Out the Tough Task of Discerning T-cell Prolymphocytic Leukemia
October 21st 2020

Review Lays Out the Tough Task of Discerning T-cell Prolymphocytic Leukemia

Jared Kaltwasser
T-cell prolymphocytic leukemia is rare and shares many features with other conditions. A new review article helps explain some of the tactics physicians can use to correctly identify it.
Pembrolizumab Expanded to Treat Relapsed, Refractory cHL in Adults, Children
October 17th 2020

Pembrolizumab Expanded to Treat Relapsed, Refractory cHL in Adults, Children

Skylar Jeremias
It is the first PD-1 inhibitor to be approved to be used as a monotherapy for the treatment of adult and pediatric patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).
Blood cells
October 15th 2020

MRD Negativity Indicative of Improved OS, DFS in AML, Study Says

Jaime Rosenberg
Based on the findings, the researchers are arguing that minimal residual disease (MRD) should be considered as a clinical trial endpoint.
Dual US, China Approval Process for Zanubrutinib Shows Regulatory Differences
October 7th 2020

Dual US, China Approval Process for Zanubrutinib Shows Regulatory Differences

Jared Kaltwasser
The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.
Case Report: Ibrutinib Might Protect Against Acute Lung Injury in Patients With CLL, COVID-19
October 2nd 2020

Case Report: Ibrutinib Might Protect Against Acute Lung Injury in Patients With CLL, COVID-19

Jared Kaltwasser
A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.
HSCT Viable for Children With Nonremission Acute Lymphoblastic Leukemia
September 30th 2020

HSCT Viable for Children With Nonremission Acute Lymphoblastic Leukemia

Jared Kaltwasser
Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.
TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says
September 23rd 2020

TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says

Jared Kaltwasser
Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.
Novel CAR T-Cell Process Shows Promise in Relapsing/Refractory B-ALL
September 18th 2020

Novel CAR T-Cell Process Shows Promise in Relapsing/Refractory B-ALL

Jared Kaltwasser
A new chimeric antigen receptor (CAR) T cell therapy may help curb the problem of frequent relapse in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Patient in Bed
September 15th 2020

25% of Patients With CLL See Disease Flare When Ibrutinib Therapy Pauses

Jared Kaltwasser
Ibrutinib can lead to side effects, causing some physicians to consider reducing the dose or temporarily halting therapy, but that risks disease flares, a new study finds.
Study Finds QOL Lags in Patients With CLL, Even Before Treatment
September 12th 2020

Study Finds QOL Lags in Patients With CLL, Even Before Treatment

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) have worse health-related quality of life scores compared to healthy controls, according to a new study out of India.
Picture of hepatitis virus
September 10th 2020

Hepatitis B More Prevalent in Patients With CLL Than Those With MM

Jared Kaltwasser
New research casts doubt on the notion that hepatitis plays a role in the development of multiple myeloma (MM), finding that the virus is actually more common in chronic lymphocytic leukemia (CLL).
Picture of ICU
September 4th 2020

Identifying the Risk of Neurotoxicity After CAR T-Cell Therapy

Jared Kaltwasser
A significant number of patients who undergo chimeric antigen receptor (CAR) T-cell therapy will experience severe neurotoxicity. A new study could help doctors better predict which patients are at risk.
CD83 Could Be Meaningful Target Against MCL, Study Finds
September 1st 2020

CD83 Could Be Meaningful Target Against MCL, Study Finds

Jared Kaltwasser
Mantle cell lymphoma is considered incurable, but a new strategy could lead to better results in a subgroup of patients with the cancer.
White blood cell
August 27th 2020

Modern Therapies, Younger Age Predict Improved Outcomes in Waldenström Macroglobulinemia

Jared Kaltwasser
Patients who are diagnosed with Waldenström macroglobulinemia (WM) at age 55 or younger tend to have low risk profiles and very high overall survival rates.
Levofloxacin Prophylaxis Shown to Be Cost-effective in Pediatric ALL, AML
August 25th 2020

Levofloxacin Prophylaxis Shown to Be Cost-effective in Pediatric ALL, AML

Jared Kaltwasser
Children receiving intensive chemotherapy benefit from prophylaxis with levofloxacin to an extent that would justify the cost of the drug, a new analysis finds.
Researchers Leverage p53 Expression to Identify TP53 Missense Mutations in MCL
August 21st 2020

Researchers Leverage p53 Expression to Identify TP53 Missense Mutations in MCL

Jaime Rosenberg
Reporting on their findings in the British Journal of Haematology, researchers have used immunohistochemistry (IHC) to leverage p53 expression as an identifier of mantle cell lymphoma (MCL) patients carrying mutations in tumor protein p53 (TP53), an indicator of poor prognosis in the disease.
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
August 16th 2020

Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects

Maggie L. Shaw
Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.
TML Helps Predict Time to Treatment in CLL and Its Precursor, Study Shows
August 15th 2020

TML Helps Predict Time to Treatment in CLL and Its Precursor, Study Shows

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) often face months or years of uncertainty. A new study might help those patients better understand their progression timeline.
Study Explores Causes of Bleeding in Patients with CLL, MCL Taking Ibrutinib
August 14th 2020

Study Explores Causes of Bleeding in Patients with CLL, MCL Taking Ibrutinib

Jared Kaltwasser
A significant proportion of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) experience bleeding when taking ibrutinib—a recent study probes why.
Novartis Says Tisagenlecleucel Met CRR in Early FL Data
August 5th 2020

Novartis Says Tisagenlecleucel Met CRR in Early FL Data

Allison Inserro
Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).
In Assessing CLL HRQoL, Type of Questionnaire Matters, Study Says
July 31st 2020

In Assessing CLL HRQoL, Type of Questionnaire Matters, Study Says

Allison Inserro
Understanding the patient point of view can help with treatment decisions as well as gauge the impact of treatment, the authors said.
Immunoglobulin Abnormalities Do Not Affect Overall Survival in CLL, Study Finds
July 31st 2020

Immunoglobulin Abnormalities Do Not Affect Overall Survival in CLL, Study Finds

Jared Kaltwasser
While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not have an impact on overall survival in patients with chronic lymphocytic leukemia (CLL).
FDA Approves CAR T-Cell Therapy for Adults With R/R Mantle Cell Lymphoma
July 25th 2020

FDA Approves CAR T-Cell Therapy for Adults With R/R Mantle Cell Lymphoma

Mary Caffrey
The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.
CLL Experts Favor Social Distancing, but Vary on Treatment Continuation Amid Pandemic
July 24th 2020

CLL Experts Favor Social Distancing, but Vary on Treatment Continuation Amid Pandemic

Jared Kaltwasser
Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.
<1
...
67891011121314
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo